Global Oral Contraceptive Pills Market is Projected to Reach US$22.9 bn by 2023

Date: 2016-01-07

Oral contraceptive pills are birth control pills including progestin and estrogen hormones. These hormones induce contraception/birth control by preventing ovulation. These pills are also known as combined pills or combined oral contraceptive pills (COCP). Combined oral contraceptive pills are available in five different packs: the 21-day pack, the 24-day pack, the 28-day pack, the 91-day pack and the four-phase regimen. Bayer’s Yaz and Loestrin are the most widely preferred brands of the 24-day pack. Barr Laboratories’ Seasonale and Teva Pharmaceutical Industries’ Seasonique are preferred in the 91-day pack sub-segment. In the four-phase regimen, Bayer’s Natazia dominates the market.

In addition to COCP, emergency contraceptive pills are being increasingly used to prevent pregnancy after unprotected sex. This treatment method is generally used for specific conditions and is not considered the regular method of birth control. Teva Pharmaceuticals’ “Plan B One-Step” is one such emergency contraceptive available over-the-counter without prescription or age restrictions. It is claimed that the consumption of Plan B One-Step as per the directions reduces the chance of pregnancy by 90%.

In terms of type of product, the market has been categorized into combination, progestin-only, and others. The combination contraceptive pills segment held the largest share of the market in 2014. The segment is projected to expand at the highest CAGR during the forecast period from 2015 to 2023, due to high efficiency against pregnancy prevention, rising preference toward combination pills, and easy availability. Moreover, growing preference toward combination pills would also account for the market growth. Based on category, the generic contraceptive pills segment dominated the oral contraceptive pills market in 2014. The segment is anticipated to expand at the highest CAGR due to widespread and universal adoption facilitated by ease of use and low prices.

The oral contraceptive pills market is growing at a steady pace due to rising awareness about contraceptives and their offered advantages in preventing pregnancy, favorable reimbursement policies in North America and high incidence rate of unintended pregnancies globally. According to a study conducted by the Centers for Disease Control and Prevention, from 2006 to 2010, 37% of the total pregnancies were unintended in the U.S. Large proportion of these unintended pregnancies resulted in abortions, which entailed preventable health care expenditure. In an attempt to curb this redundant health care expenditure, the governments of various countries including developed and developing nations such as the U.S., Sweden, Norway and India are encouraging women to opt for more effective modern contraceptive pills.

Major players currently operating in the oral contraceptive pills market include Actavis, Inc., Bayer AG, Church & Dwight, Co., Inc., Merck & Co., Inc., Pfizer, Inc., and Teva Pharmaceutical Industries Ltd.


Contact With Us
Join templatemonster at google+
Customized Research
Request Sample